Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Membranes (Basel) ; 13(2)2023 Jan 29.
Article in English | MEDLINE | ID: mdl-36837671

ABSTRACT

Plasmid DNA is used as a vector for gene therapy and DNA vaccination; therefore, the establishment of a mass production method is required. Membrane filtration is widely employed as a separation method suitable for the mass production of plasmid DNA. Furthermore, the separation of plasmid DNA using microfiltration and ultrafiltration membranes is being investigated. Because plasmid DNA has a circular structure, it undergoes significant deformation during filtration and easily permeates the membrane, hindering the selection of separation membranes based on molecular weight. In this study, we applied affinity microfiltration to plasmid DNA purification. α-Fe2O3 with an isoelectric point of approximately 8 and a particle size of 0.5 µm was selected as the ligand for two-stage affinity microfiltration of plasmid DNA. In the first stage of microfiltration, the experiment was conducted at a pH of 5, and a cake of α-Fe2O3 with bound plasmid DNA was obtained. Next, liquid permeation (pH 9 and 10) through the cake was performed to elute the bound plasmid DNA. Plasmid DNA was eluted during the early phase of liquid permeation at pH 10. Furthermore, agarose gel analysis confirmed the usefulness of the two-stage affinity microfiltration method with adsorption and desorption for plasmid DNA purification.

2.
Membranes (Basel) ; 13(1)2023 Jan 07.
Article in English | MEDLINE | ID: mdl-36676881

ABSTRACT

The recycling of extracellular polymeric substances (EPSs) from excess sludge in wastewater treatment plants has received increasing attention in recent years. Although membrane separation has great potential for use in EPS concentration and recovery, conventional membranes tend to exhibit low water flux and high energy consumption. Herein, electrospun nanofiber membranes (ENMs) were fabricated using polyvinylidene fluoride (PVDF) and used for the recovery of EPSs extracted from the excess sludge using the cation exchange resin (CER) method. The fabricated ENM containing 14 wt.% PVDF showed excellent properties, with a high average water flux (376.8 L/(m2·h)) and an excellent EPS recovery rate (94.1%) in the dead-end filtration of a 1.0 g/L EPS solution at 20 kPa. The ENMs displayed excellent mechanical strength, antifouling properties, and high reusability after five recycles. The filtration pressure had a negligible effect on the average EPS recovery rate and water flux. The novel dead-end filtration with an EPS filter cake on the ENM surface was effective in removing heavy-metal ions, with the removal rates of Pb2+, Cu2+, and Cr6+ being 89.5%, 73.5%, and 74.6%, respectively. These results indicate the potential of nanofiber membranes for use in effective concentration and recycling of EPSs via membrane separation.

3.
Membranes (Basel) ; 11(2)2021 Jan 27.
Article in English | MEDLINE | ID: mdl-33513956

ABSTRACT

Microfiltration is widely used to remove microbial cells from the fermentation broth in the downstream processing of biotechnological products. Because filtration behaviors are strongly affected by the characteristics of the microbial cell cake formed on the surface of the membrane, insights into the cake structure facilitate the design and operation of filter equipment and membranes. In the alcohol fermentation process using a yeast strain, the cake characteristics are considered to be complicated because yeast cells are strongly influenced by external factors such as filtration pressure and alcohol concentration. In this study, we evaluated the membrane filtration properties, in particular the cake characteristics of a yeast suspension containing alcohol. Microfiltration experiments were performed in the dead-end filtration mode using yeast suspensions with several ethanol concentrations (0-20 wt%) under constant pressure. Flux decline behaviors caused by yeast cake were put in a similar form for 0-15 wt% ethanol concentrations. In contrast, a severe flux decline was observed for the suspension with 20 wt% ethanol concentration. It was also observed that in the membrane filtration of yeast cells with 20 wt% ethanol concentration, the cake structure became denser and the filtration resistance remarkably increased because of cellular destruction. Furthermore, the yeast cake exhibited a high compressibility in the solution containing a 20 wt% ethanol concentration. Therefore, the filtration rate of the alcoholic fermentation broth is not significantly improved by increased pressure due to the increase in the cake resistance.

4.
Forensic Sci Int ; 266: 1-7, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27161293

ABSTRACT

Population aging is rapidly advancing in numerous parts of the world and, accordingly, the prevalence of Alzheimer's disease (AD) is rising. The safety of donepezil (DPZ), which is used for AD treatment, has been established in clinical trials. However, some studies have indicated that DPZ may be associated with severe cardiac side effects, and excessive doses may induce toxicity-related symptoms or death. Therefore, the measurement of blood DPZ levels is important for the postmortem investigation of related causes of death. However, postmortem drug concentrations in the blood may not always reflect those obtained antemortem because of the postmortem redistribution (PMR) of drugs. Therefore, the aim of this study was to investigate the potential PMR of DPZ using a rat model. The DPZ concentration was measured using a validated HPLC/Q-TOF-MS system in cardiac and peripheral blood, and in the brain, lungs, myocardium, liver, and thigh muscle at different postmortem intervals (0, 1, 3, 6, 12, and 24h). Overall, the DPZ tissue to peripheral blood ratio decreased throughout the postmortem period. Furthermore, the DPZ concentration increased in the peripheral and cardiac blood but decreased in both of the lungs, postmortem. Furthermore, the blood pH was significantly lowered. We used a perfusion approach to examine the rat lung and heart to further investigate the relationship between the pH and DPZ release from the lungs. The outflow concentrations when the inflow pH changed from 7.4 to 5.5 were approximately 2-fold higher than the inflow pH fixed 7.4. These findings suggest that the antemortem accumulated DPZ in the lungs is released into the pulmonary blood owing to postmortem acidification of blood, and subsequently flows into the cardiac blood, leading to the observed increase in concentration. Although we could not determine the underlying mechanism, we confirmed that PMR occurs similarly in the cardiac and peripheral blood.


Subject(s)
Cholinesterase Inhibitors/metabolism , Indans/metabolism , Piperidines/metabolism , Alzheimer Disease/drug therapy , Alzheimer Disease/pathology , Animals , Autopsy , Blood Chemical Analysis , Cholinesterase Inhibitors/analysis , Cholinesterase Inhibitors/blood , Cholinesterase Inhibitors/therapeutic use , Donepezil , Hydrogen-Ion Concentration , Indans/analysis , Indans/blood , Indans/therapeutic use , Piperidines/analysis , Piperidines/blood , Piperidines/therapeutic use , Postmortem Changes , Rats , Time Factors , Tissue Distribution
5.
Biol Pharm Bull ; 38(1): 134-8, 2015.
Article in English | MEDLINE | ID: mdl-25342005

ABSTRACT

Psilocin (3-[2-(dimethylamino)ethyl]-1H-indol-4-ol) is a hallucinogenic component of the Mexican mushroom Psilocybe mexicana and a skeletal serotonin (5-HT) analogue. Psilocin is the active metabolite of psilocybin (3-[2-(dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate). In the present study, we examined the effects of systemically administered psilocin on extracellular dopamine and 5-HT concentrations in the ventral tegmental area (VTA), nucleus accumbens, and medial prefrontal cortex of the dopaminergic pathway in awake rats using in vivo microdialysis. Intraperitoneal administration of psilocin (5, 10 mg/kg) significantly increased extracellular dopamine levels in the nucleus accumbens. Psilocin did not affect the extracellular 5-HT level in the nucleus accumbens. Conversely, systemic administration of psilocin (10 mg/kg) significantly increased extracellular 5-HT levels in the medial prefrontal cortex of rats, but dopamine was decreased in this region. However, neither extracellular dopamine nor 5-HT levels in the VTA were altered by administration of psilocin. Behaviorally, psilocin significantly increased the number of head twitches. Thus, psilocin affects the dopaminergic system in the nucleus accumbens. In the serotonergic system, psilocin contribute to a crucial effect in the medial prefrontal cortex. The present data suggest that psilocin increased both the extracellular dopamine and 5-HT concentrations in the mesoaccumbens and/or mesocortical pathway.


Subject(s)
Dopamine/metabolism , Hallucinogens/pharmacology , Nucleus Accumbens/drug effects , Prefrontal Cortex/drug effects , Psilocybin/analogs & derivatives , Serotonin/metabolism , Animals , Male , Nucleus Accumbens/metabolism , Prefrontal Cortex/metabolism , Psilocybin/pharmacology , Rats, Wistar , Ventral Tegmental Area/drug effects , Ventral Tegmental Area/metabolism
6.
Pharmacol Rep ; 65(5): 1204-12, 2013.
Article in English | MEDLINE | ID: mdl-24399716

ABSTRACT

BACKGROUND: Selegiline, a therapeutic drug for Parkinson's disease (PD), structurally resembles the endogenous parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline (TIQ). In the present study, we evaluated the effects of 3-methyl-TIQ (3-MeTIQ) and 3-methyl-N-propargyl-TIQ (3-Me-N-proTIQ), selegiline mimetic TIQ derivatives, for preventing 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism-like symptoms in mice. METHODS: We evaluated the preventative effects of 3-MeTIQ and 3-Me-N-proTIQ on MPTP-induced bradykinesia and depletion of striatal dopamine (DA) and nigral tyrosine hydroxylase (TH)-positive cells. RESULTS: MPTP-induced bradykinesia was not different when mice were pretreated with 3-MeTIQ, except for the high-dose group. However, pretreatment with 3-Me-N-proTIQ significantly prevented the appearance of this akinesic status. MPTP-induced striatal DA and 3,4-dehydroxyphenylacetic acid reduction were significantly prevented by pretreatment with 3-Me-N-proTIQ, but not 3-MeTIQ, in a dose-dependent manner. On the other hand, levels of serotonin and its metabolite, 5-hydroxyindole acetic acid, in the striatum were increased following treatment with 3-MeTIQ. In addition, the MPTP-induced decrease in TH-positive cells in the substantia nigra was significantly reduced by pretreatment with 3-Me-N-proTIQ, but not 3-MeTIQ. CONCLUSIONS: These results suggest that not only does 3-Me-N-proTIQ have potential as a candidate compound for disease-modifying therapy for PD, but also the N-propargyl functional group plays an important role in neuroprotection.


Subject(s)
Antiparkinson Agents/pharmacology , Behavior, Animal/drug effects , MPTP Poisoning/prevention & control , Neuroprotective Agents/pharmacology , Tetrahydroisoquinolines/pharmacology , Animals , Basal Ganglia/drug effects , Basal Ganglia/metabolism , Disease Models, Animal , Dopamine/metabolism , Dose-Response Relationship, Drug , Hydroxyindoleacetic Acid/metabolism , Hypokinesia/metabolism , Hypokinesia/prevention & control , Hypokinesia/psychology , MPTP Poisoning/metabolism , MPTP Poisoning/psychology , Male , Mice , Mice, Inbred C57BL , Motor Activity/drug effects , Serotonin/metabolism , Substantia Nigra/drug effects , Substantia Nigra/metabolism , Time Factors , Tyrosine 3-Monooxygenase/metabolism
7.
J Pharmacol Sci ; 120(3): 187-95, 2012.
Article in English | MEDLINE | ID: mdl-23090716

ABSTRACT

Peripheral neuropathic pain is a serious side effect of paclitaxel treatment. However, the mechanism of this paclitaxel-induced neuropathic pain is unknown. In this study, we investigated the effects of paclitaxel on the voltage-dependent calcium channel (VDCC) current in rat dorsal root ganglion (DRG) neurons using the whole-cell patch clamp technique. Behavioral assessment using von Frey filament stimuli showed that 2 and 4 mg/kg paclitaxel treatment induced mechanical allodynia/hyperalgesia. Paclitaxel-induced mechanical hyperalgesia was significantly inhibited by gabapentin (100 mg/kg). Using the patch clamp method, we observed that paclitaxel (4 mg/kg) treatment significantly increased the VDCC current in small- and medium-diameter DRG neurons. Moreover, paclitaxel-induced increase in the VDCC current in medium-diameter DRG neurons was completely inhibited by 10 and 100 µM gabapentin. Similar effects in small-diameter DRG neurons were only seen with 100 µM gabapentin. Western blotting revealed that paclitaxel increased protein levels of the VDCC subunit α2δ-1 (Ca(v)α2δ-1) in DRG neurons. Immunohistochemistry showed that paclitaxel treatment increased Ca(v)α2δ-1 protein expression in DRG neurons. Thus, paclitaxel treatment increases the VDCC current in small- and medium-diameter DRG neurons and upregulates Ca(v)α2δ-1. The antihyperalgesic action of gabapentin may be due to inhibition of paclitaxel-induced increases in the VDCC current in DRG neurons.


Subject(s)
Action Potentials/drug effects , Antineoplastic Agents, Phytogenic/pharmacology , Calcium Channel Agonists/pharmacology , Ganglia, Spinal/drug effects , Neurons/drug effects , Paclitaxel/pharmacology , Up-Regulation/drug effects , Animals , Antineoplastic Agents, Phytogenic/adverse effects , Behavior, Animal/drug effects , Calcium Channel Agonists/adverse effects , Calcium Channel Blockers/therapeutic use , Calcium Channels/chemistry , Calcium Channels/metabolism , Calcium Channels, L-Type , Cell Size , Cells, Cultured , Ganglia, Spinal/cytology , Ganglia, Spinal/metabolism , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Hyperalgesia/metabolism , Male , Nerve Tissue Proteins/agonists , Nerve Tissue Proteins/antagonists & inhibitors , Nerve Tissue Proteins/metabolism , Neuralgia/chemically induced , Neuralgia/drug therapy , Neuralgia/metabolism , Neurons/cytology , Neurons/metabolism , Neurotoxicity Syndromes/drug therapy , Neurotoxicity Syndromes/metabolism , Paclitaxel/adverse effects , Rats , Rats, Wistar
8.
Brain Res ; 1321: 133-42, 2010 Mar 19.
Article in English | MEDLINE | ID: mdl-20114039

ABSTRACT

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is well known as an exogenous dopaminergic neurotoxin that induces Parkinson's disease-like symptoms. In addition, 1,2,3,4-tetrahydroisoquinoline (TIQ) derivatives have been investigated as endogenous MPTP mimetic compounds that structurally resemble selegiline, a commercially available drug for treating Parkinson's disease. In the present study, we examined the ability of 1,3-dimethyl-TIQ (1,3-diMeTIQ) and 1,3-dimethyl-N-propargyl-TIQ (1,3-diMe-N-proTIQ) to prevent MPTP-induced Parkinson's disease-like symptoms in mice and to prevent 1-methyl-4-phenylpyridinium ion (MPP+, an active metabolite of MPTP)-induced cytotoxicity in vitro, including its structural stereoselectivity. Repeated administration of MPTP induced bradykinesia, a symptom of behavioral abnormality; this was prevented by both 1,3-diMeTIQ and 1,3-diMe-N-proTIQ pretreatments. Pretreatment with 1,3-diMeTIQ did not prevent the MPTP-induced decrease in dopamine content in the striatum or the decrease in the number of tyrosine hydroxylase-positive cells in the substantia nigra. On the other hand, 1,3-diMe-N-proTIQ prevented these Parkinson's disease-like symptoms; in particular, the trans-isomer of this agent showed potent protective effects. However, the ability of the trans-1,3-diMe-N-proTIQ isomer to prevent MPP+-induced PC12 cell death was weaker than that of its cis-isomer. Thus, stereoisomers of 1,3-diMe-N-proTIQ exhibit different effects; cis-1,3-diMe-N-proTIQ inhibits MPP+-induced cytotoxicity while trans-1,3-diMe-N-proTIQ exhibits neuroprotective effects primarily through MPTP-related biological events in mice. These results also indicate the possibility of utilizing, at least in part, the stereoselective efficacy of 1,3-diMe-N-proTIQ against MPTP and/or MPP+-induced adverse states.


Subject(s)
Neuroprotective Agents/pharmacology , Parkinsonian Disorders/prevention & control , Tetrahydroisoquinolines/pharmacology , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Hypokinesia/chemically induced , Hypokinesia/metabolism , Hypokinesia/prevention & control , Immunohistochemistry , Mice , Neuroprotective Agents/chemistry , Parkinsonian Disorders/metabolism , Parkinsonian Disorders/pathology , Stereoisomerism , Tetrahydroisoquinolines/chemistry
9.
Brain Res ; 1269: 40-6, 2009 May 07.
Article in English | MEDLINE | ID: mdl-19285043

ABSTRACT

It is known that psychostimulants stimulate dopamine transmission in the nucleus accumbens. In the present study, we examined the effects of systemically administered beta-phenylethylamine (beta-PEA), a psychomotor-stimulating trace amine, on dopamine concentrations in the nucleus accumbens and prefrontal cortex in freely moving rats, using an in vivo microdialysis technique. Intraperitoneal administration of beta-PEA (12.5 and 25 mg/kg) significantly increased extracellular dopamine levels in the nucleus accumbens shell. The observed increase in the dopamine concentration in nucleus accumbens shell dialysate after intraperitoneal administration of 25 mg/kg beta-PEA was inhibited by pre-treatment with a dopamine uptake inhibitor, GBR12909 (10 mg/kg, i.p.). In contrast, beta-PEA (25 mg/kg, i.p.) did not affect dopamine release in the nucleus accumbens core. Although a high dose of beta-PEA (50 mg/kg) significantly increased dopamine levels in the nucleus accumbens core, the dopamine increasing effect of beta-PEA was more potent in the nucleus accumbens shell. Systemic administration of 12.5 and 25 mg/kg beta-PEA also increased extracellular dopamine levels in the prefrontal cortex of rats. However, systemic 25 mg/kg beta-PEA-induced increases in extracellular dopamine levels were not blocked by GBR12909 within the prefrontal cortex. These results suggest that beta-PEA has a greater effect in the shell than in the core and low-dose beta-PEA stimulates dopamine release in the nucleus accumbens shell through uptake by a dopamine transporter. Similarly, beta-PEA increased extracellular dopamine levels in the prefrontal cortex. Thus, beta-PEA may increase extracellular dopamine concentrations in the mesocorticolimbic pathway.


Subject(s)
Dopamine/metabolism , Nucleus Accumbens/drug effects , Phenethylamines/pharmacology , Prefrontal Cortex/drug effects , Psychotropic Drugs/pharmacology , Animals , Dopamine Uptake Inhibitors/pharmacology , Extracellular Space/metabolism , Injections, Intraperitoneal , Male , Microdialysis , Nucleus Accumbens/metabolism , Piperazines/pharmacology , Prefrontal Cortex/metabolism , Rats , Rats, Wistar
10.
J Pharmacol Exp Ther ; 314(2): 916-22, 2005 Aug.
Article in English | MEDLINE | ID: mdl-15879004

ABSTRACT

The effects of systemic administration of beta-phenylethylamine (beta-PEA) and microiontophoretically applied beta-PEA on the spontaneous discharge of dopamine (DA) neurons in the ventral tegmental area (VTA) of the anesthetized rat were examined. Intravenous administration of beta-PEA (1.0, 2.5, and 5.0 mg/kg) and microiontophoretic applications of beta-PEA caused inhibitory responses in DA neurons. Systemic administration and microiontophoretic applications of beta-PEA induced dose- or current-dependent responses. The systemic beta-PEA-induced inhibitory responses were reversed by pretreatment with the DA D(2) receptor antagonists haloperidol (0.5 mg/kg i.p.) and sulpiride (10 mg/kg i.p). Pretreatment with reserpine (5 mg/kg i.p. 24 h earlier) did not completely block the systemic administration of beta-PEA (2.5 mg/kg) inhibition. A microdialysis study of freely moving rats demonstrated that the extracellular DA level increased significantly in response to local application of beta-PEA (100 muM) in the VTA via a microdialysis probe, and local application of beta-PEA-stimulated somatodendritic DA release in the VTA. The beta-PEA-induced release of DA was calcium ion-independent and was enhanced by pretreatment with pertussis toxin. These findings indicate that beta-phenylethylamine inhibits DA neuron activity via DA D(2) autoreceptors in the rat VTA and that this inhibitory effect is mediated by the somatodendritic DA release.


Subject(s)
Dopamine/physiology , Neurons/drug effects , Phenethylamines/pharmacology , Ventral Tegmental Area/drug effects , Animals , Calcium/physiology , Electrophysiology , Iontophoresis , Male , Microdialysis , Rats , Rats, Wistar , Ventral Tegmental Area/cytology
SELECTION OF CITATIONS
SEARCH DETAIL
...